Giorgia Guglielmi
Modifying the microbiota could influence multiple sclerosis progression and provide new therapeutic targets.
Gut microbes adapt to exercise demands, favoring energy production over bacterial diversity.
Targeting TudS could be a potential therapeutic approach for treating C. difficile infections.
Each Fusobacterium nucleatum population has unique traits and distribution patterns across body sites and conditions such as colorectal cancer and Crohn’s disease.
Gut microbiota-produced bile acids can be used as therapeutic targets for multiple sclerosis.
Targeting E. lenta or boosting neutrophil function may lead to new treatment strategies for bronchiectasis and related lung diseases.
Nutrient competition is the main mechanism of C. difficile inhibition, hinting at the potential for targeted therapies with probiotics instead of traditional FMT.
Introducing more natural microbes could improve astronauts’ health.
Researchers have developed new tools to better understand the role of Bifidobacterium breve, revealing its competitive growth strategies and potential for supporting the immune system.
Delayed microbiota maturation in infants with cystic fibrosis could contribute to disease complications, highlighting potential therapeutic targets.
